周围血液中的改变表面活性蛋白基因表达与COVID-19疾病严重程度有关吗?
Suna Koc1, Kamil Cankut Senturk2, Sefa Cetinkaya3
1Department of Anesthesia and Reanimation, School of Medicine, Biruni University, Istanbul 34015, Turkey.
COVID-19的严重程度显著改变了血液中的表面活性蛋白基因表达. 严重的病例显示表面活性蛋白B和C减少,表面活性蛋白A2和D增加,表明肺损伤机制.
科学领域:
- 肺部医学 肺部医学
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 严重的COVID-19肺炎会影响气膜细胞和表面活性剂的平衡,导致ARDS.
- 表面活性蛋白 (SP-A,SP-B,SP-C,SP-D) 对于肺功能和免疫防御至关重要.
- 了解COVID-19中表面活性剂基因表达对于评估疾病严重程度至关重要.
研究的目的:
- 调查COVID-19严重程度与外周血液中表面活性蛋白基因表达之间的相关性.
- 在疾病分类方面量化SFTPA1,SFTPA2,SFTPB,SFTPC和SFTPD的mRNA水平.
主要方法:
- 从122名成年COVID-19患者收集了无症状,轻度和重度类别的外周血液.
- 在血液细胞中使用RT-qPCR量化表面活性蛋白基因mRNA表达.
- 将GAPDH标准化表达式,并使用2^-ΔΔCt方法分析差异,不包括异常值.
主要成果:
- 随着COVID-19严重程度的增加,SFTPB和SFTPC基因表达减少.
- 在轻度病例中,SFTPC显著上升,但在严重病例中下降.
- 与轻度和无症状组相比,SFTPA2和SFTPD在严重的COVID-19病例中显示出戏剧性的上调.
结论:
- COVID-19的严重程度与血液表面活性剂基因表达的显著变化密切相关.
- 严重的疾病包括SP-B和SP-C转录的损失和夸张的SP-D反应.
- 这些表达模式可能表明导致肺损伤的不平衡,SP-D作为严重性生物标志物的潜力.
更多相关视频
09:03Nasal Brushing Sampling and Processing Using Digital High Speed Ciliary Videomicroscopy – Adaptation for the COVID-19 Pandemic
Published on: November 7, 2020
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
相关概念视频
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Breathing
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
